AMRX Market Analysis
Wall Street coverage
third-party contextWall Street coverage
$20.25median target· current $18.32 (+10.5%)4 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
50 articles · sorted by datePage 1 of 3 · 50 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeP/E ratio38.17Forward 6.30
EPS (TTM)$0.48157.1% YoY
Profit margin5.1%HEALTHCARE
Market cap$5.85BMid cap
Valuation
- Forward P/E
- 6.30
- PEG ratio
- —
- P/B
- 177.20
- P/S (TTM)
- 1.88
- EV/EBITDA
- 13.67
Profitability & growth
- ROE (TTM)
- 61.3%
- Operating margin
- 18.4%
- Revenue growth YoY
- 9.9%
- Dividend yield
- —
- Beta
- 1.26
Last earnings
Jul 30, 2026 · Estimate $0.24 · Reported $0.27
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Amneal Pharmaceuticals, Inc. Class A Common Stock
Company profileAmneal Pharmaceuticals, Inc. develops, licenses, manufactures, markets and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company is headquartered in Bridgewater, New Jersey.
Classification
- Sector
- Healthcare
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 400 CROSSING BOULEVARD, BRIDGEWATER, NJ
- Fiscal year end
- December
- Latest quarter
- Jun 30, 2026
Market cap$5.85B
Shares outstanding$319.3M
52W high$19.26
52W low$7.80
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent